Accounts receivable, net of allowance for credit losses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses | Accounts receivable, net of allowance for credit losses The following table provides details of the Company’s allowance for credit losses on accounts receivable:
Accounts receivable were $1,134,551 and $1,176,620, and allowances for credit losses were $18,278 and $16,833, resulting in net accounts receivable balances of $1,116,273 and $1,159,787 as of December 31, 2023 and June 30, 2024, respectively. In addition, deferred billings were $90,094 and $97,180 and allowances for credit losses on deferred billings were $4,096 and $5,512, resulting in net deferred billings balances of $85,998 and $91,668 as of December 31, 2023 and June 30, 2024, respectively. During the three months ended June 30, 2023 and 2024, the Company recorded a charge of $147 and $1,338, respectively, and for the six months ended June 30, 2023 and 2024, a charge of $147 and $4,416, respectively, to the income statement on account of credit losses on deferred billings. Deferred billings, net of related allowances for credit losses, are included under “Other assets” in the Company’s consolidated balance sheet as of December 31, 2023 and June 30, 2024. 3. Accounts receivable, net of allowance for credit losses (Continued) The Company has a revolving accounts receivable-based facility of $75,000 as of December 31, 2023 and June 30, 2024, permitting it to sell accounts receivable to banks on a non-recourse basis in the ordinary course of business. The aggregate maximum capacity utilized by the Company at any time during the period ended December 31, 2023 and June 30, 2024 was $51,367 and $52,031, respectively. The principal amount outstanding against this facility as of December 31, 2023 and June 30, 2024 was $51,344 and $51,977, respectively. The cost of factoring such accounts receivable during the three and six months ended June 30, 2023 and 2024 was $453 and $720, respectively, and $914 and $1,426, respectively. Gains or losses on the sales are recorded at the time of transfer of the accounts receivable and are included under "interest income (expense), net" in the Company’s consolidated statements of income. The Company also has arrangements with financial institutions that manage the accounts payable program for certain of the Company's large clients. The Company sells certain accounts receivable pertaining to such clients to these financial institutions on a non-recourse basis. There is no cap on the value of accounts receivable that can be sold under these arrangements. The Company used these arrangements to sell accounts receivable amounting to $324,401 during the year ended December 31, 2023, and $129,238 during the six months ended June 30, 2024, which also represents the maximum capacity utilized under these arrangements in each such period. The cost of factoring such accounts receivable during the three and six months ended June 30, 2023 and 2024 was $2,570 and $1,866, respectively, and $3,970 and $3,041, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||